Do not forget on Sedar this document of company .October 20Commercializing Aristotle® • Market to four channels as discussed on slide 16; physician practices, employers, heath care systems, and directly to patients • Beginning process with a novel group of cancer clinics • In discussions with large healthcare systems and several self-funded employer plans
-Come for COVID, Stay for Cancer
-Telehealth and COVID-19 • Leverage the Company’s MyCancerRisk telehealth platform to request COVID-19 test and communicate results; many physicians offices are closed; many patients are at home; a solution is telehealth and mobile phlebotomists •
-The Company believes that COVID-19 is expected to remain an active virus affecting human populations for the next 15-21 months New Partners •
-Mercer’s VIP Program • Companies/Employers eg: travel groups/airlines •
-Large Physician Groups eg: urgent care centers • States, Counties, Cities
- Aristotle® • Publish data, clinically validate, prepare for first commercial launch
Telehealth for COVID-19 & Beyond – What We’ve Built....
- • Online store for taking secure payments
- • Network of physicians who are licensed in all fifty (50) states to prescribe tests and follow-up on elevated scores
- • Adopted a HIPAA1 compliant portal solution to collect and protect patient data
- • Grown network to 8,000+ draw sites and 10,000 mobile phlebotomists in US through the Company’s partner physicians
-The Sentinel Principle® – Patented Technology • Circulating blood reflects, in a detectable way, what is occurring throughout the body • Subtle changes that occur in cells due to disease trigger detectable changes in mRNA expression1 • The Company’s flagship test derived from the Sentinel Principle®, known as ColonSentry®, measures the expression levels of seven genes (ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, IL2RB, and VNN1) • Validated in a study of 10,000 patients in North America2 • Demonstrated to find cancer early (Stage 1 and 2), but also at Stage 3 and 4 3 • Elevated test results are highly predictive of left and right sided colorectal cancer4 • Negative predictive value is 99.6%4